Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + toripalimab versus gemcitabine + cisplatin/carboplatin for first-line HER2-expressing advanced or metastatic urothelial carcinoma
CTR20220348Phase 3Active
- Sponsor
- RemeGen
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin, toripalimab in transitional cell carcinoma (TCC), sponsored by RemeGen. Started Jun 2022; status: active.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20220348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220348.